Last reviewed · How we verify
KPG-818 high dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
KPG-818 high dose (KPG-818 high dose) — Kangpu Biopharmaceuticals, Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| KPG-818 high dose TARGET | KPG-818 high dose | Kangpu Biopharmaceuticals, Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- KPG-818 high dose CI watch — RSS
- KPG-818 high dose CI watch — Atom
- KPG-818 high dose CI watch — JSON
- KPG-818 high dose alone — RSS
Cite this brief
Drug Landscape (2026). KPG-818 high dose — Competitive Intelligence Brief. https://druglandscape.com/ci/kpg-818-high-dose. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing